

DIASORIN LAUNCHES THE EHEC TOXINS TEST FOR EARLY DETECTION OF ENTEROHAEMORRHAGIC E. COLI INFECTIONS ON STOOL SAMPLES TO BE PERFORMED ON ITS LIAISON PLATFORM

October 25, 2013 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce that it launched the **EHEC Toxins test on its LIAISON platform** for the market outside the US, Canada and UK only.

The **LIAISON EHEC Toxins assay** is intended for the qualitative detection of Shiga toxins 1 and 2 **in stool samples** and is an aid in the diagnosis of *Enterohaemorrhagic E. coli* (EHEC) with **CLIA technology**.

Enterohaemorrhagic E. coli is a bacterium that can cause severe foodborne disease.

In most cases, the illness is self-limiting, but it may lead to a life-threatening disease including **Haemolytic Uraemic Syndrome (HUS)**, especially in young children and the elderly.

It is estimated that **up to 10%** of patients with EHEC infection **may develop HUS**, with a **case-fatality rate** ranging **from 3 to 5%**.

Overall, **HUS** is the most common cause of **acute renal failure in young children** and it can cause **neurological complications** (*e.g. seizure, stroke and coma*) **in 25% of HUS patients** and **chronic renal sequelae**, usually mild, in around **50% of survivors**.

The bacterium is transmitted to humans primarily **through consumption of contaminated foods**, such as raw or undercooked ground meat products, raw milk and contaminated raw vegetables and sprout. Faecal contamination of water and other foods, as well as cross-contamination during food preparation, will also lead to infection.

The **reservoir** of this pathogen appears to be mainly **cattle**. In addition, **other ruminants** such as **sheep, goats, deer** are considered significant reservoirs, while **other mammals** (*pigs, horses, rabbits, dogs, cats*) and **birds** (*chickens, turkeys*) have been occasionally found infected.

According to last estimates, **only in Europe the number of tests performed for E. coli using CLIA technology is around 5.5 million tests per year**, for a total value of around **10 million Euros** in the European market, including tests performed with other technologies.

The launch of the new LIAISON EHEC toxins assay provides a **complete, automatic and consolidated solution** to a new potential clients base where manual labor is still the most common and problematic solution.

This test is an **addition to the DiaSorin's stool menu already available on the market** (*C. difficile Toxin A&B, C. difficile GDH, H. Pylori*) and shows our commitment to rapidly increase the stool panel that establishes **DiaSorin as a key player** in this microbiology field.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	Enterohaemorrhagic E. Coli Toxins		
Diagnosis	qualitative detection of EHEC Toxins 1 and 2 in Stool samples		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potencial market	~ € 10 mln in Europe		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		HLA Typing
Clinical Area	Infectious Disease		Infectious Disease
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral		Onco-hematology
	Cardiac Markers		
	GI Stool Testing	✓	

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: “With the launch of this test we demonstrate, once again, our commitment to the development of a fully automated offer on stool sample that enables us to address the needs of laboratories that still use manual and problematic solutions.

Furthermore this test is of key importance for public health authorities that need to diagnose fast the EHEC Toxin in order to prevent any possible future outbreak”.

About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”. For more information, please visit www.diasorin.com

For additional information, please contact:

Riccardo Fava

External Relations Director - Head of IR and Media

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it